Gland Pharma Limited

Gland Pharma Limited (GLAND) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

glandpharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-09-02

Stock price
₹2868.40
Market cap
47,278 Cr
Stock P/E
39.2
P/B
4.56
Dividend yield
0.6%

Sign in for full ratios and TTM. Learn about these metrics →

Share price

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,373 Cr1,545 Cr1,537 Cr1,402 Cr1,406 Cr1,384 Cr1,425 Cr1,506 Cr1,487 Cr1,695 Cr1,743 Cr1,800 Cr
Operating expenses (approx.)1,049 Cr1,189 Cr1,179 Cr1,137 Cr1,109 Cr1,024 Cr1,077 Cr1,138 Cr1,173 Cr1,260 Cr1,230 Cr1,311 Cr
EBITDA324 Cr356 Cr359 Cr264 Cr297 Cr360 Cr348 Cr368 Cr314 Cr435 Cr513 Cr489 Cr
OPM %23.6%23.1%23.3%18.9%21.1%26.0%24.4%24.4%21.1%25.7%29.4%27.2%
Other income53 Cr37 Cr42 Cr51 Cr60 Cr58 Cr44 Cr58 Cr84 Cr63 Cr111 Cr61 Cr
Interest6 Cr5 Cr10 Cr6 Cr6 Cr23 Cr7 Cr11 Cr8 Cr4 Cr10 Cr4 Cr
Depreciation81 Cr105 Cr93 Cr92 Cr94 Cr96 Cr96 Cr101 Cr106 Cr108 Cr109 Cr111 Cr
Profit before tax290 Cr283 Cr298 Cr218 Cr257 Cr299 Cr288 Cr313 Cr284 Cr362 Cr506 Cr435 Cr
Tax %33.0%32.2%35.5%34.1%36.3%31.6%35.3%31.1%35.3%27.8%27.5%27.1%
Net profit194 Cr192 Cr192 Cr144 Cr164 Cr205 Cr187 Cr215 Cr184 Cr261 Cr367 Cr317 Cr
EPS (₹)₹11.78₹11.65₹11.68₹8.73₹9.93₹12.42₹11.32₹13.08₹11.15₹15.87₹22.26₹19.23

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,463 Cr4,401 Cr3,625 Cr5,665 Cr5,617 Cr6,431 CrSign in for TTM
Operating expenses (approx.)2,161 Cr2,891 Cr2,600 Cr4,332 Cr4,348 Cr4,801 CrSign in for TTM
EBITDA1,302 Cr1,510 Cr1,025 Cr1,333 Cr1,269 Cr1,630 CrSign in for TTM
OPM %37.6%34.3%28.3%23.5%22.6%25.3%Sign in for TTM
Other income135 Cr224 Cr240 Cr170 Cr214 Cr316 CrSign in for TTM
Interest3 Cr5 Cr7 Cr26 Cr42 Cr33 CrSign in for TTM
Depreciation99 Cr110 Cr147 Cr345 Cr378 Cr424 CrSign in for TTM
Profit before tax1,335 Cr1,619 Cr1,055 Cr1,133 Cr1,063 Cr1,465 CrSign in for TTM
Tax %25.3%25.1%25.9%31.8%34.3%29.9%Sign in for TTM
Net profit997 Cr1,212 Cr781 Cr772 Cr699 Cr1,027 CrSign in for TTM
EPS (₹)₹63.07₹73.81₹47.44₹46.90₹42.40₹62.35Sign in for TTM
Dividend payout %—0.0%0.0%0.0%47.2%28.9%Sign in for TTM
Sign in for TTM

Trailing twelve months totals and margin rows

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr
Reserves5,887 Cr7,141 Cr7,942 Cr8,707 Cr9,134 Cr10,341 Cr
Borrowings4 Cr4 Cr4 Cr320 Cr269 Cr243 Cr
Other liabilities589 Cr672 Cr815 Cr1,618 Cr1,805 Cr1,910 Cr
Total liabilities6,496 Cr7,834 Cr8,778 Cr10,661 Cr11,225 Cr12,511 Cr
Fixed assets (net)953 Cr1,499 Cr1,559 Cr3,541 Cr3,751 Cr4,052 Cr
CWIP338 Cr181 Cr177 Cr238 Cr151 Cr342 Cr
Investments0 Cr155 Cr0 Cr0 Cr0 Cr0 Cr
Loans & advances0.25 Cr0.47 Cr0.14 Cr0 Cr0 Cr0 Cr
Inventories1,275 Cr1,186 Cr1,945 Cr1,655 Cr1,685 Cr1,744 Cr
Trade receivables671 Cr1,199 Cr871 Cr1,559 Cr1,517 Cr1,891 Cr
Cash & bank492 Cr319 Cr1,909 Cr357 Cr2,556 Cr3,359 Cr
Other assets2,766 Cr3,295 Cr2,316 Cr3,311 Cr1,566 Cr1,122 Cr
Total assets6,496 Cr7,834 Cr8,778 Cr10,661 Cr11,225 Cr12,511 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity—791 Cr364 Cr997 Cr915 Cr1,031 Cr
Cash from investing—-1,003 Cr1,208 Cr-1,757 Cr1,705 Cr138 Cr
Cash from financing—35 Cr15 Cr-799 Cr-433 Cr-417 Cr
Net cash flow—-174 Cr1,590 Cr-1,552 Cr2,199 Cr803 Cr
Free cash flow (OCF − Capex)—269 Cr141 Cr599 Cr521 Cr537 Cr

Ratios

Ratios as reported or derived per annual period.

MetricMar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %22.7%22.7%13.3%12.8%11.7%14.1%
ROE %16.9%16.9%9.8%8.9%7.6%9.9%
Debtor days71998810098107
Inventory days265211412299311283
Days payable8382125156151136
Cash conversion cycle253228375243258255
Debt / equity0.00070.000.00050.040.030.02
Current ratio10.0010.059.464.044.334.68
Net debt / EBITDA0.000.00-1.86-0.03-1.80-1.91

Compare with peers

Loading peers…